课题基金 / 基金详情

The development of novel therapeutic strategies for targeting ovarian cancer stem cells

The development of novel therapeutic strategies for targeting ovarian cancer stem cells
针对卵巢癌干细胞的新型治疗策略的开发
批准号:
21390454
负责人:
KATABUCHI Hidetaka
金额:
$11.32万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2009
资助国家:
日本
项目状态:
已结题
起止时间:
2009 至 2011

项目摘要

项目成果

KATABUCHI Hidetaka的其他基金

相似基金

相关文献

中文摘要
翻译
新出现的证据表明,人类癌症起源于正常的干细胞,由肿瘤启动细胞(t - ic)维持的细胞层次组成,概念上称为癌症干细胞(CSCs)。上皮细胞粘附分子(Epithelial cell adhesion molecule, EpCAM)是一种I型跨膜糖蛋白,在上皮组织中特异性表达,在一些上皮癌中过表达。在正常组织中,EpCAM在几种类型的上皮干细胞/祖细胞中表达,并有助于组织发育。另一方面,epcam阳性细胞亚群已被确定为某些人类癌症中的CSCs。基于这些考虑,我们在成年小鼠卵巢中评估了epcam阳性细胞的干细胞特性,并通过在epcam阳性细胞中引入定义的遗传元件建立了卵巢t - ic。epcam阳性细胞在卵巢肿瘤发生小鼠模型中具有体细胞干细胞和CSCs的特征。此外,我们的实验小鼠模型有助于进一步研究卵巢正常干细胞和CSCs的全面认识。最终,这样的研究将是必要的,以确定根除卵巢csc是否对有效治疗至关重要。
英文摘要
Emerging evidence suggests that human cancers arise from normal stem cells, and are composed of hierarchies of cells sustained by tumor-initiating cells(T-ICs), conceptually termed cancer stem cells(CSCs). Epithelial cell adhesion molecule(EpCAM) is a type I transmembrane glycoprotein that is expressed specifically in epithelial tissues and is overexpressed in some epithelial cancers. In normal tissues, EpCAM is expressed in several types of epithelial stem/progenitor cells and contributes to tissue development. On the other hand, a subpopulation of EpCAM-positive cells has been identified as CSCs in some human cancers. In the light of these considerations, we evaluated the EpCAM-positive cells for their stem cell properties in adult mouse ovary, and established the ovarian T-ICs by introduction of defined genetic elements in EpCAM-positive cells. EpCAM-positive cells possess the hallmarks of somatic stem cells and CSCs in this mouse model of ovarian tumorigenesis. Furthermore, our experimental mouse model facilitates further studies toward a comprehensive understanding of normal stem cells and CSCs in ovary. Ultimately, such studies will be imperative to define whether eradication of ovarian CSCs is critical for effective therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Short RNA duplexes elicit RIG-1-mediated apoptosis in a cell type- and length-dependent manner
短RNA双链体以细胞类型和长度依赖性方式引发RIG-1介导的细胞凋亡
DOI: --
发表时间: 2011
期刊: Science Signaling
影响因子: 7.3
作者: [Ishibashi O, et al]
通讯作者: et al
DOI: 10.1016/j.ccr.2011.01.038
发表时间: 2011-03-15
期刊: CANCER CELL
影响因子: 50.3
作者: [Ishimoto, Takatsugu, Nagano, Osamu, Saya, Hideyuki]
通讯作者: Saya, Hideyuki
Special lecture「A new tool to investigate the tumorigenesis and therapeutic modalities of epithelial ovarian cancer」
特别讲座“研究上皮性卵巢癌肿瘤发生和治疗方式的新工具”
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [Ogata, S., Morishige, K., Sawada, K., Hashimoto, K., Mabuchi, S., Kawase, C., Ooyagi, C., Sakata, M., Kimura, T., H. Katabuchi]
通讯作者: H. Katabuchi
Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies : a novel insight to the molecular pathogenesis of ovarian epithelial carcinoma.
卵巢浆液性癌与砂粒体的长期肿瘤学结果:对卵巢上皮癌分子发病机制的新见解。
DOI: --
发表时间: 2010
期刊: Cancer Science
影响因子: 5.7
作者: [T.Motohara, H.Tashiro, et al.]
通讯作者: et al.
共 17 条
    An ovarian carcinoma model using immortalized human ovarian surface epithelial cells without chromosomal instability
    • 批准号:
      18390450
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.49万
    • 财政年份:
      2006
    • 负责人:
      KATABUCHI Hidetaka
    • 依托单位:
    Functional analysis of LH/hCG receptor in human placental chorionic villous macrophages
    • 批准号:
      15591763
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2003
    • 负责人:
      KATABUCHI Hidetaka
    • 依托单位:
    Characterization of immortalized human ovarian surface epithelial cells transfected by PTEN expression vectors
    • 批准号:
      12671616
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      2000
    • 负责人:
      KATABUCHI Hidetaka
    • 依托单位:
    海外基金